T. Rowe Price Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $402M | Sell |
|
|||||
|
2025
Q1 | $1.38B | Buy |
|
|||||
|
2024
Q4 | $1.49B | Buy |
|
|||||
|
2024
Q3 | $1.34B | Buy |
|
|||||
|
2024
Q2 | $980M | Buy |
|
|||||
|
2024
Q1 | $869M | Buy |
|
|||||
|
2023
Q4 | $631M | Sell |
|
|||||
|
2023
Q3 | $1.83B | Sell |
|
|||||
|
2023
Q2 | $1.62B | Buy |
|
|||||
|
2023
Q1 | $1.79B | Buy |
|
|||||
|
2022
Q4 | $1.24B | Sell |
|
|||||
|
2022
Q3 | $1.21B | Buy |
|
|||||
|
2022
Q2 | $1B | Buy |
|
|||||
|
2022
Q1 | $615M | Sell |
|
|||||
|
2021
Q4 | $577M | Buy |
|
|||||
|
2021
Q3 | $490M | Sell |
|
|||||
|
2021
Q2 | $461M | Sell |
|
|||||
|
2021
Q1 | $408M | Sell |
|
|||||
|
2020
Q4 | $419M | Sell |
|
|||||
|
2020
Q3 | $512M | Sell |
|
|||||
|
2020
Q2 | $701M | Buy |
|
|||||
|
2020
Q1 | $492M | Buy |
|
|||||
|
2019
Q4 | $297M | Sell |
|
|||||
|
2019
Q3 | $241M | Buy |
|
|||||
|
2019
Q2 | $252M | Sell |
|
|||||
|
2019
Q1 | $722M | Buy |
|
|||||
|
2018
Q4 | $242M | Buy |
|
|||||
|
2018
Q3 | $238M | Sell |
|
|||||
|
2018
Q2 | $243M | Buy |
|
|||||
|
2018
Q1 | $238M | Sell |
|
|||||
|
2017
Q4 | $267M | Sell |
|
|||||
|
2017
Q3 | $345M | Sell |
|
|||||
|
2017
Q2 | $402M | Sell |
|
|||||
|
2017
Q1 | $431M | Buy |
|
|||||
|
2016
Q4 | $396M | Sell |
|
|||||
|
2016
Q3 | $481M | Sell |
|
|||||
|
2016
Q2 | $634M | Sell |
|
|||||
|
2016
Q1 | $1.45B | Sell |
|
|||||
|
2015
Q4 | $2.57B | Sell |
|
|||||
|
2015
Q3 | $2.23B | Buy |
|
|||||
|
2015
Q2 | $2.17B | Buy |
|
|||||
|
2015
Q1 | $1.75B | Sell |
|
|||||
|
2014
Q4 | $1.62B | Buy |
|
|||||
|
2014
Q3 | $1.18B | Buy |
|
|||||
|
2014
Q2 | $789M | Sell |
|
|||||
|
2014
Q1 | $1.23B | Sell |
|
|||||
|
2013
Q4 | $1.65B | Buy |
|
|||||
|
2013
Q3 | $1.88B | Sell |
|
|||||
|
2013
Q2 | $1.42B | Buy |
|